![](https://endpts.com/wp-content/uploads/2019/05/ed-kaye-tile-via-stoke-therapeutics.jpg)
Ed Kaye. Stoke Therapeutics
Preclinical antisense biotech, led by former Sarepta CEO Kaye, vaults on to Nasdaq with upsized IPO
Less than a year after raising $90 million in its second round of financing, former Sarepta chief Edward Kaye is making the leap to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.